Regeneron teams up with BioNTech in melanoma (NASDAQ:REGN
published 31.07.2020 09:07
Regeneron Pharmaceuticals (NASDAQ:REGN) will collaborate with BioNTech SE (NASDAQ:BNTX) on a clinical trial evaluating the combination of PD-1 inhibitor Libtayo (cemiplimab) and the latter's BNT111 FixVac candidate for the second-line treatment of patients with advanced cutaneous melanoma.
The parties will equally share development costs for the trial and will supply their respective products.
Each will also retain full commercial rights for their respective products.
BNT111, comprised of four melanoma antigens (NY-ESO-1, MAGE-A3, tyrosinase, and TPTE), is the most advanced FixVac candidate in the BNTX's pipeline.